Open Access 240 Compound Collection Launched in Fight Against Infectious and Mosquito-Borne Illnesses
Health Policy Watch reported that the Global Health Priority Box has been launched to provide free access to 240 compounds to stimulate research into new drugs and insecticides. The initiative, launched by the Medicines for Malaria Venture (MMV) and the Innovative Vector Control Consortium, provides scientists with starting points to advance the development
Comments Off on Open Access 240 Compound Collection Launched in Fight Against Infectious and Mosquito-Borne Illnesses • Read this story »
More Articles
Open Innovation in the Healthcare Ecosystem – A Systematic Review
The Research Square website posted a study concerning the uses of the healthcare sector of open innovation. Results show that most experiments concentrate on the areas of pharmaceutical research (drug discovery) and health informatics (health information systems and infrastructures) that were brought
Comments Off on Open Innovation in the Healthcare Ecosystem – A Systematic Review • Read this story »
Korean Firms Repurpose FDA-approved Drug for Rheumatoid Arthritis Treatment
The BioSpectrum website reported that Standigm Inc, an artificial intelligence-based drug discovery company and SK Chemicals Co, Ltd, a life science and green chemicals company have announced that they have successfully found a new rheumatoid arthritis indication for an FDA-approved drug and have filed
Comments Off on Korean Firms Repurpose FDA-approved Drug for Rheumatoid Arthritis Treatment • Read this story »
Are New Drug Development Platforms Leading Pharma Innovation?
The European Pharmaceutical Manufacturer site noted that increasingly, the business model for drug discovery and development is predicated on recouping costs barely manageable for first-world, affluent nations. In an effort to combat this trend, various stakeholders in the drug discovery ecosystem have
Comments Off on Are New Drug Development Platforms Leading Pharma Innovation? • Read this story »
Growing Adoption of Open Innovation Models in Pharmaceutical and Biotechnology Companies
The GlobalNewswire website noted that a new study has been released reporting that the growing adoption of open innovation models in pharmaceutical and biotechnology companies and increasing pharmaceutical outsourcing are the key factors driving the growth of the protein stability analysis market. The
Comments Off on Growing Adoption of Open Innovation Models in Pharmaceutical and Biotechnology Companies • Read this story »
Daiichi Sankyo to Lead Open Innovation Research on Cell Therapy
The BioSpectrumAsia website reported that Daiichi Sankyo Company, Mitsubishi UFJ Capital Co., and Tokyo Institute of Technology have announced that they will commence open innovation research with the aim of creating insulin producing cells from iPS cells for use in regenerative medicine and cell
Comments Off on Daiichi Sankyo to Lead Open Innovation Research on Cell Therapy • Read this story »
A Joint Front: Open Source Pharma
An article on the Business Today (India) website noted that an open source drug discovery program allows capabilities to be linked and used, at negligible cost. India has already taken a step in this direction. Bill Gates, who built his empire on proprietary software, tweeted that open innovation
Comments Off on A Joint Front: Open Source Pharma • Read this story »
Innovation in the Open
An article on the Chemistry World website noted a trend in open innovation: rather than drawing start-ups closer to obtain their intellectual property, some firms are shifting to a more collaborative approach. This strategy foresees collaboration agreements, or business support, and subsequent shared
Comments Off on Innovation in the Open • Read this story »
Mark Samuels on Open Innovation in Pharma
The Pharma Times Online website posted an interview with Mark Samuels, chief business and strategy officer of the new Medicines Discovery Catapult, on the role of open innovation in big pharma: “I think collaborative research is increasingly important. Benefits of open innovation include access
Comments Off on Mark Samuels on Open Innovation in Pharma • Read this story »
AstraZeneca CEO Heralds New Era of Collaboration
The Cambridge Independent website reported that AstraZeneca CEO Pascal Soriot announced that the company’s advanced drug discovery robot, NiCoLA-B, will be housed in the biopharmaceutical company’s new £500million global research and development center, heralding a new era of openness and
Comments Off on AstraZeneca CEO Heralds New Era of Collaboration • Read this story »